The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Merck to Pay $688M to Settle Vytorin Lawsuits

Posted on February 20, 2013 by Andrew Findley

NewsInferno; February 18, 2013

After reportedly reaching an agreement in principle, Merck has reached a settlement in which it will pay $688 million to resolve two class-action lawsuits over its cholesterol drug, Vytorin (ezetimibe/simvastatin).

Merck said it reached the agreement in principle with plaintiffs who alleged that drug makers Merck and Schering-Plough put off releasing the details of unfavorable clinical trial results, specifically from the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial, said Cardiovascular Business.

ENHANCE involved 720 patients who were diagnosed with heterozygous familial hypercholesterolemia and who either received ezetimibe/simvastatin 10/80 mg or simvastatin 80 mg alone over a two-year period.

According to Cardiovascular Business, the plaintiffs were a group of investors who purchased securities issued by Merck and Schering-Plough between December 2006 and March 2008. The plaintiffs claim they suffered losses when the ENHANCE trial results were published in early 2008.

The lawsuits are pending in the U.S. District Court for the District of New Jersey against Merck and Schering-Plough, as well as some current and former officers and directors, said Cardiovascular Business. Merck and Schering-Plough jointly marketed Vytorin.

Under the proposal, Merck will pay $215 million to resolve the securities class action against the Merck defendants and $473 million to resolve the securities class action against the Schering-Plough defendants, said Cardiovascular Business, citing the proposed agreement. The agreement, which is subject to court approval, contains no admission of liability or wrongdoing.

Merck recorded a pre-tax and after-tax charge of $493 million, an anticipation of insurance recoveries and in connection with the settlement, Cardiovascular Business reported.

Meanwhile, we previously wrote that people who use statins such as Vytorin to lower their cholesterol may face a higher risk of developing age-related cataracts, according to a study published late last year in Optometry and Vision Science. According to the study, the association between statins and cataracts may be equal to the association with Type 2 diabetes, a known risk factor for age-relegated cataracts. That’s significant, because statin use is generally higher among Type 2 diabetics, compared to the general population. Statins, which are used to lower blood cholesterol levels, rank among the best selling drugs in the world.

Prior to that, we wrote that the U.S. Food & Drug Administration (FDA) warned that statins, including Vytorin, cannot only raise blood sugar levels, but may cause memory loss. The labels for the drugs were updated to include information about these possible statin side effects.

http://www.newsinferno.com/?p=42867

 

Posted in Blog

Comments are closed.

Recent Posts

Salmon Purchasers Reach an $85 Million Price Fixing Settlement

Salmon Purchasers Reach an $85 Million Price Fixing Settlement

May 27th, 2022

According to Reuters, who had seen the proposed settlement after it was filed on 25 May, the settlement will r[Read More...]
Ford Agrees to Pay $19 Million to Settle False Fuel Economy and Payload Claims

Ford Agrees to Pay $19 Million to Settle False Fuel Economy and Payload Claims

May 27th, 2022

Ford Motor Company as agreed to a $19.2 million multistate settlement among 40 attorneys general that concluded an investigat[Read More...]
Total Settlement in Surfside Condo Collapse Tops $1 Billion

Total Settlement in Surfside Condo Collapse Tops $1 Billion

May 25th, 2022

The proposed settlement reached nearly a year after the catastrophic Surfside building collapse along the South Flo[Read More...]
UCLA Will Pay Nearly $700 Million in Abuse Lawsuits

UCLA Will Pay Nearly $700 Million in Abuse Lawsuits

May 25th, 2022

The University of California system announced Tuesday it will pay nearly $375 million to more than 300 women who said they we[Read More...]
Things to Consider When You Sue an Insurance Provider

Things to Consider When You Sue an Insurance Provider

May 24th, 2022

We are all too acquainted with insurance coverage in our everyday lives. According to Investopedia, everyone should have[Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.